Carmat funding, investors and company details

Carmat is an emerging Healthcare startup from [●], working in the space of Artificial heart is developed, manufactured, and commercialized. Founded by Alain Carpentier.

Company: Carmat SA
Sector: Healthcare
Location: [●]
Founders: Alain Carpentier
Total funding raised: ₹61.61 Cr

Company overview

The Aeson artificial heart is developed, manufactured, and commercialized by Carmat, a French MedTech company focused on innovative solutions for advanced heart failure. The device has been designed as a total artificial heart intended to replace the function of a failing human heart in patients suffering from end-stage biventricular heart failure. Carmat developed the Aeson artificial heart in response to the global shortage of human donor hearts available for transplantation. Due to the limited availability of suitable donor organs, many patients with severe heart failure are unable to receive timely transplants. The company aims to address this critical gap by providing a reliable and effective alternative.

Funding rounds

Latest round: $ 7.40 Mn (₹61.61 Cr.), 2023-10-16